Affiliation:
1. Amsterdam University Medical Center, University of Amsterdam
2. University Medical Center Rotterdam
3. Amsterdam University Medical Centers
Abstract
Abstract
PurposeLimited sampling strategies (LSS) lower the burden of PK-guided dosing, but an extensive evaluation of LSS for BAX 855 (Adynovi®) is currently lacking. This study aimed to develop a LSS for BAX 855 and combine this with a LSS of a standard half-life (SHL) FVIII concentrate in a clinical setting. MethodsIndividual PK parameters of BAX 855 were estimated for 10,000 virtual patients with severe hemophilia A using Monte Carlo simulations. Several LSS consisting of 2-6 samples were examined based on patient burden, bias and accuracy of clearance, elimination half-life, volume of distribution and trough levels at 72h (C72). Analyses were performed separately for adults and children <12 years.ResultsThe preferred LSS for BAX 855 consisted of three sampling points at 15-30 min, 48h and 72h for both adults (mean accuracy C72: 14.0% vs. 10.8% using six samples) and children (mean accuracy C72: 14.9% vs. 11.4% using six samples). The best strategy with two samples (peak, 48 hours) resulted in an adequate, but lower accuracy than strategies with ≥3 samples (mean accuracy C72: 22.3%). The optimal combination of the LSS of SHL FVIII and BAX 855 led to six samples during four clinical visits.ConclusionThis in silico study has identified that two to three samples are necessary to estimate the individual PK of BAX-855 adequately. These samples can be collected in one or two clinical visits. When combining PK profiling of SHL FVIII and BAX 855, six samples during four clinical visits are needed.
Publisher
Research Square Platform LLC
Reference29 articles.
1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia;Manco-Johnson MJ;N Engl J Med,2007
2. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics To Age and Body Weight;Björkman S;Blood,2012
3. Srivastava A, Santagostino E, Dougall A, et al (2020) WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26:1–158. https://doi.org/10.1111/hae.14046
4. Lee M, Morfini M, Schulman S, Ingerslev J (2001) The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. https://www.isth.org/members/group_content_view.asp?group=100348&id=159244. Accessed 26 May 2021
5. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH;Iorio A;J Thromb Haemost,2017